Goldman initiated coverage on Alkermes Plc with a new price target
$ALKS
Biotechnology: Pharmaceutical Preparations
Health Care
Goldman initiated coverage of Alkermes Plc with a rating of Buy and set a new price target of $43.00
Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/15/2025 | $43.00 | Buy | Goldman |
| 6/17/2025 | $42.00 | Neutral → Buy | UBS |
| 5/28/2025 | $45.00 | Buy | Needham |
| 3/13/2025 | $40.00 | Sector Perform | RBC Capital Mkts |
| 3/4/2025 | $21.00 → $38.00 | Sell → Neutral | UBS |
| 2/11/2025 | $40.00 | Buy | Deutsche Bank |
| 11/5/2024 | $25.00 → $36.00 | Hold → Buy | Stifel |
| 6/17/2024 | $34.00 | Buy | TD Cowen |
4 - Alkermes plc. (0001520262) (Issuer)
4 - Alkermes plc. (0001520262) (Issuer)
4 - Alkermes plc. (0001520262) (Issuer)
Goldman initiated coverage of Alkermes Plc with a rating of Buy and set a new price target of $43.00
UBS upgraded Alkermes Plc from Neutral to Buy and set a new price target of $42.00
Needham initiated coverage of Alkermes Plc with a rating of Buy and set a new price target of $45.00
S-8 - Alkermes plc. (0001520262) (Filer)
10-Q - Alkermes plc. (0001520262) (Filer)
8-K - Alkermes plc. (0001520262) (Filer)
— Second Quarter Revenues of $390.7 Million — — GAAP Net Income of $87.1 Million and Diluted GAAP Earnings per Share of $0.52 — — Company Reiterates 2025 Financial Expectations — — Alkermes to Present Detailed Vibrance-1 Results at Upcoming World Sleep Congress — DUBLIN, July 29, 2025 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) today reported financial results for the second quarter of 2025. "Our second quarter results reflect strong performance across all three of our proprietary products and robust profitability and cash flow generation," said Richard Pops, Chief Executive Officer of Alkermes. "Against the backdrop of solid financial performance, the recently announced positive
– Alixorexton Demonstrated Clinically Meaningful and Statistically Significant Improvements in Wakefulness at All Doses Tested Compared to Placebo in Patients With Narcolepsy Type 1 – – Alixorexton Demonstrated Robust and Consistent Improvements in Patient-Reported Outcomes Related to Disease Severity, Fatigue and Cognition at All Doses Tested – – Alixorexton Was Generally Well Tolerated at All Doses Tested – – Detailed Results to Be Presented at Upcoming World Sleep Congress – – Data Support Advancement of Alixorexton to Phase 3 Development in Narcolepsy – DUBLIN, July 21, 2025 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) today announced positive topline results from the randomized double-bli
DUBLIN, July 15, 2025 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Tuesday, July 29, 2025 to discuss the company's second quarter financial results. The webcast player and accompanying slides may be accessed on the Investors section of Alkermes' website at www.alkermes.com. The conference call may be accessed by dialing +1 877 407 2988 for U.S. callers and +1 201 389 0923 for international callers. A replay of the webcast will be available approximately two hours after the completion of the event and may be accessed by visiting Alkermes' website. About Alkermes plcAlkermes plc is a global biopharmaceutical
DUBLIN, March 7, 2024 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) today announced the appointment of a new independent director, Nancy S. Lurker, to the company's Board of Directors (the Board). Ms. Lurker is a seasoned healthcare executive and experienced board member who brings decades of pharmaceutical and biotechnology industry leadership experience and strong commercial expertise, including a track record of successful U.S. and global pharmaceutical product launches. "Nancy brings to the Board deep biopharmaceutical industry experience spanning executive leadership, govern
NEW YORK, Dec. 1, 2023 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, December 18, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from t
— Dr. Loew to Assume New Leadership Role Upon Completion of the Planned Separation of Alkermes' Oncology Business — — Planned Separation Remains on Track to be Completed in Second Half of 2023 — DUBLIN, June 1, 2023 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) today announced that Caroline J. Loew, Ph.D., has been appointed as the chief executive officer designate of Mural Oncology plc (Mural Oncology), the new independent public company to be established upon the planned separation of Alkermes' oncology business. Dr. Loew will join Alkermes in June as a strategic advisor and transition to CEO of Mural Oncology upon completion of the separation. "Dr. Loew's deep knowledge of the oncology fi
SC 13G - Alkermes plc. (0001520262) (Subject)
SC 13G/A - Alkermes plc. (0001520262) (Subject)
SC 13G/A - Alkermes plc. (0001520262) (Subject)
— Second Quarter Revenues of $390.7 Million — — GAAP Net Income of $87.1 Million and Diluted GAAP Earnings per Share of $0.52 — — Company Reiterates 2025 Financial Expectations — — Alkermes to Present Detailed Vibrance-1 Results at Upcoming World Sleep Congress — DUBLIN, July 29, 2025 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) today reported financial results for the second quarter of 2025. "Our second quarter results reflect strong performance across all three of our proprietary products and robust profitability and cash flow generation," said Richard Pops, Chief Executive Officer of Alkermes. "Against the backdrop of solid financial performance, the recently announced positive
DUBLIN, July 15, 2025 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Tuesday, July 29, 2025 to discuss the company's second quarter financial results. The webcast player and accompanying slides may be accessed on the Investors section of Alkermes' website at www.alkermes.com. The conference call may be accessed by dialing +1 877 407 2988 for U.S. callers and +1 201 389 0923 for international callers. A replay of the webcast will be available approximately two hours after the completion of the event and may be accessed by visiting Alkermes' website. About Alkermes plcAlkermes plc is a global biopharmaceutical
— First Quarter Revenues of $306.5 Million — — GAAP Net Income of $22.5 Million and Diluted GAAP Earnings per Share of $0.13 — — Company Reiterates 2025 Financial Expectations — DUBLIN, May 1, 2025 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) today reported financial results for the first quarter of 2025. "Our first quarter financial performance provides a solid foundation to deliver on our financial guidance for the year. We are in a strong position in this dynamic macroeconomic environment and remain focused on executing on the strategic objectives that we believe will drive the future value of the company," said Richard Pops, Chief Executive Officer of Alkermes. "We recently achiev